Aldosterone antagonists in heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Aldosterone antagonists, including spironolactone and eplerenone, are approved for symptomatic heart failure with reduced ejection fraction.
• These drugs exhibit cardioprotective, antifibrotic, and antiarrhythmic properties demonstrated in preclinical and clinical studies.

Purpose of the Study:

• To highlight the underutilization of aldosterone antagonists in heart failure management.
• To emphasize the importance of patient selection for mitigating risks, primarily hyperkalemia.

Main Methods:

• Review of existing randomized clinical trials and animal experiments on aldosterone antagonists.
• Discussion of clinical practice guidelines and evidence regarding hyperkalemia risk management.

Main Results:

• Aldosterone antagonists have proven benefits in reducing morbidity and mortality in heart failure patients.
• Fear of hyperkalemia is a significant barrier to the widespread prescription of these medications.

Conclusions:

• Optimizing the use of aldosterone antagonists requires meticulous patient screening and selection.
• Further research and ongoing trials may expand indications to milder heart failure or preserved systolic function.